Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After one Bay Area IPO got a ...

US biotech Eikon Therapeutics (Nasdaq: EIKN) has raised about $381 million in the largest biotech IPO of the year so far, but the market’s first reaction was cautious. Shares fell nearly 17% on their ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Eikon Therapeutics shares were down 6%, at $16.90, in the stock's first day of trade on the Nasdaq Global Select Market. Shares of the clinical-stage biopharmaceutical company began trading midday ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the ...

Shares of Eikon Therapeutics are set to begin trading Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the top of expectations. Eikon late ...

Eikon Therapeutics Inc. shares fell 17% on Thursday after the late-stage cancer drug developer raised $381.2 million in an upsized US initial public offering. Shares of the company, which is led by ...